Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
144 pending office actions • 51 art units • 116 examiners • 1 of 144 (1%) have an AI response strategy ready • 164 patents granted in the last 365 days
Regeneron Pharmaceuticals Inc. currently has 144 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 117 distinct examiners, which is a smaller number than the total 144 pending office actions. The portfolio involves 50 distinct art units, suggesting a broad technical scope for the company's filings. KIM, YUNSOO is the busiest examiner, currently overseeing 4 pending office actions.
The 117 distinct examiners involved indicate that many examiners are responsible for more than one case for the company. This wide distribution across 50 distinct art units requires the company to manage diverse procedural requirements within Biotechnology & Pharmaceuticals. KIM, YUNSOO, with 4 pending office actions, holds a higher individual workload than the other distinct examiners. Practitioners should monitor the 144 pending office actions for consistency across the 50 distinct art units.
The 50 distinct art units represent a significant range of technical examination standards that the company must meet. With 144 pending office actions, the volume of work is substantial relative to the 4 pending office actions assigned to KIM, YUNSOO. Understanding the specific preferences of the 117 distinct examiners is crucial for successful prosecution across the portfolio.
Based on the USPTO statutory response window for each pending office action. 42 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 42 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 18 (12%) |
| §103 only | 30 (21%) |
| §102 only | 3 (2%) |
| §112 only | 23 (16%) |
| Double-patenting only | 2 (1%) |
| Double-patenting + other | 24 (17%) |
| Multi-statute (no §101) | 38 (26%) |
| No statute on record | 6 (4%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YUNSOO | 4 | 65.9% | +34.3% |
| WILSON, MICHAEL C | 4 | 41.5% | +17.9% |
| STONEBRAKER, ALYSSA RAE | 4 | 58.3% | +49.2% |
| HOWARD, ZACHARY C | 3 | 64.0% | +37.9% |
| XU, XIAOYUN | 3 | 60.0% | +31.8% |
| LI, RUIXIANG | 2 | 59.5% | +18.6% |
| ROONEY, NORA MAUREEN | 2 | 60.3% | +23.6% |
| FRITCHMAN, REBECCA M | 2 | 45.7% | +35.3% |
| MARCSISIN, ELLEN JEAN | 2 | 34.5% | +49.3% |
| KAPUSHOC, STEPHEN THOMAS | 2 | 46.5% | +53.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18130980 | COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST | HOWARD, ZACHARY C | 127d overdue |
| 18051488 | Association Of T Cell Leukemia/Lymphoma Protein 1A (TCL1A) With Clonal Hematopoiesis Of Indeterminate Potential (CHIP) | KAPUSHOC, STEPHEN THOMAS | 73d overdue |
| 19187394 | SYSTEMS AND METHODS FOR A REGULATORY-COMPLIANT AUTOMATED ASSAY | THOMPSON, CURTIS A | 46d overdue |
| 18336148 | SYSTEMS AND METHODS FOR DRUG DELIVERY TO OCULAR TISSUE | MEDWAY, SCOTT J | 25d overdue |
| 17954999 | ASSAYS TO QUANTITATE DRUG AND TARGET CONCENTRATIONS | EVANS, CHRISTOPHER RYAN | 4d overdue |
| 17041252 | GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS OF MAKING AND USES THEREOF | WILSON, MICHAEL C | 4d overdue |
| 18187564 | PRECISION DOSE DELIVERY DEVICE PLUNGER ROD INSERTION GAUGE AND METHODS THEREFOR | NGUYEN, ANDREW H | 2d overdue |
| 17433887 | ADENO-ASSOCIATED VIRUS VECTORS FOR THE DELIVERY OF THERAPEUTICS | LEONARD, ARTHUR S | 6d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18130980 | COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST | HOWARD, ZACHARY C | 127d overdue |
| 18051488 | Association Of T Cell Leukemia/Lymphoma Protein 1A (TCL1A) With Clonal Hematopoiesis Of Indeterminate Potential (CHIP) | KAPUSHOC, STEPHEN THOMAS | 73d overdue |
| 17684674 | SYSTEMS AND METHODS FOR QUANTIFYING AND MODIFYING PROTEIN VISCOSITY | XU, XIAOYUN | 31d overdue |
| 17041252 | GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS OF MAKING AND USES THEREOF | WILSON, MICHAEL C | 4d overdue |
| 19248893 | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREBY | KIM, YUNSOO | 8d |
| 19333264 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | LI, RUIXIANG | 43d |
| 17870368 | NATIVE MICROFLUIDIC CE-MS ANALYSIS OF ANTIBODY CHARGE HETEROGENEITY | XU, XIAOYUN | 55d |
| 19217541 | PROCESS FOR REDUCING SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION | KIM, YUNSOO | — |
| Art Unit | Apps |
|---|---|
| 1642 | 9 |
| 1641 | 8 |
| 1675 | 7 |
| 1674 | 6 |
| 1638 | 6 |
| 1634 | 6 |
| 1643 | 6 |
| 1637 | 5 |
| 1636 | 4 |
| 1631 | 4 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19333264 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | LI, RUIXIANG | 1674 | §103 | Non-Final OA | 43d | Pending | Sep 18, 2025 |
| 19248893 | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREBY | KIM, YUNSOO | 1641 | §112DP | Non-Final OA | 8d | Pending | Jun 25, 2025 |
| 19217541 | PROCESS FOR REDUCING SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION | KIM, YUNSOO | 1641 | §102DP | Non-Final OA | — | Pending | May 23, 2025 |
| 19187394 | SYSTEMS AND METHODS FOR A REGULATORY-COMPLIANT AUTOMATED ASSAY | THOMPSON, CURTIS A | 1798 | §101§103 | Final Rejection | 46d overdue | Pending | Apr 23, 2025 |
| 19057507 | MICROCHIP CAPILLARY ELECTROPHORESIS ASSAYS AND REAGENTS | BALL, JOHN C | 1795 | §103§112Other | Non-Final OA | — | Pending | Feb 19, 2025 |
| 18945863 | SYSTEMS AND METHODS FOR PRODUCING SMALL-SCALE MIXERS FOR DRUG MANUFACTURING | PATEL, VISHAL I | 1746 | §103 | Non-Final OA | — | Pending | Nov 13, 2024 |
| 18942224 | ASPARAGINE FEED STRATEGIES TO IMPROVE CELL CULTURE PERFORMANCE AND MITIGATE ASPARAGINE SEQUENCE VARIANTS | SINGH, SATYENDRA K | — | §103 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18802201 | NON-HUMAN ANIMALS HAVING A HUMANIZED LYMPHOCYTE-ACTIVATION GENE 3 | WRIGHT, ERIC BRANDON | — | §112 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18798198 | Treatment Of Hyperglycemia With Solute Carrier Family 39 Member 5 (SLC39A5) Inhibitors | KONOPKA, CATHERINE ANNE | 1635 | §103§112DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18785975 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | RICCI, CRAIG D | 1611 | §102§112Other | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18786335 | METHODOLOGY TO CHARACTERIZE EMPTY-FULL RATIO IN CRUDE AAV SAMPLES | GILL, RACHEL B | — | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18777757 | SYSTEMS AND METHODS FOR MOTOR ASSESSMENT | EDWARDS, ETHAN WESLEY | — | §101§103 | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18776820 | METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST | HOWARD, ZACHARY C | 1674 | Other | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18763490 | METHODS AND COMPOSITIONS FOR MODIFYING A TARGETED LOCUS | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18734482 | LOW AFFINITY FcyR DEFICIENT MICE | WILSON, MICHAEL C | 1638 | §112Other | Non-Final OA | — | Pending | Jun 05, 2024 |
| 18674399 | METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS | HOWARD, ZACHARY C | 1674 | §112Other | Non-Final OA | — | Pending | May 24, 2024 |
| 18670684 | Chimeric Antigen Receptors with BCMA Specificity and Uses Thereof | BURKHART, MICHAEL D | — | — | Non-Final OA | — | Pending | May 21, 2024 |
| 18670314 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | LU, CHENG | 1642 | §103DP | Non-Final OA | — | Pending | May 21, 2024 |
| 18669172 | Anti-CTLA-4 Antibodies and Uses Thereof | ROONEY, NORA MAUREEN | — | §112DP | Non-Final OA | — | Pending | May 20, 2024 |
| 18666742 | AUTO-INJECTOR AND RELATED METHODS OF USE | EGLOFF, PETER RICHARD | — | §102§103 | Non-Final OA | — | Pending | May 16, 2024 |
| 18659538 | SYSTEMS AND METHODS FOR REDUCING SAMPLE SIZES | ERICKSON, BENNETT S | 3683 | §101§103 | Non-Final OA | — | Pending | May 09, 2024 |
| 18637055 | CONCENTRATION-DEPENDENT SELF-INTERACTION ASSAY | NGUYEN, NAM P | — | §102§103§112 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18634633 | SYSTEMS, METHODS, AND APPARATUSES FOR IMPROVED INSTRUMENT MONITORING AND ANALYTICS | MINCEY, JERMAINE A | — | §101§102§103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18699454 | STEREOCILIN PROMOTERS AND USES THEREOF | MOLOYE, TITILAYO | — | — | Non-Final OA | — | Pending | Apr 08, 2024 |
| 18606302 | Proteomic Risk Score For Osteoarthritis (OA) | FRITCHMAN, REBECCA M | — | §101§103§112 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18604573 | METHODS FOR OBTAINING ANTIBODY MOLECULES WITH HIGH AFFINITY | MARCSISIN, ELLEN JEAN | — | §103§112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18592388 | ANTI-FEL D1 ANTIBODY FORMULATIONS | KIM, YUNSOO | — | §103DP | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18589384 | MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF | METCALF, MATTHEW CURRAN | — | §102§103DP | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18582159 | Treatment Of Obesity In Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR) | KAPUSHOC, STEPHEN THOMAS | 1683 | §112DP | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18436306 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | GONZALEZ, LUISALBERTO | 1624 | §112 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18432780 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | LI, RUIXIANG | — | §112Other | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18421538 | CHARACTERIZATION OF SERINE-LYSINE CROSS-LINK IN ANTIBODY HIGH MOLECULAR WEIGHT SPECIES | COLE, HOUSTON DAVID | — | §101§102§103§112 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18420090 | SYSTEMS AND METHODS FOR MOBILE AND STATIC BIOMETRIC MOVEMENT TRACKING | DING, XIAOMAO | 2676 | §103 | Final Rejection | 1d overdue | Pending | Jan 23, 2024 |
| 18580810 | IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | ALLEN, MARIANNE P | — | §112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18413096 | RODENTS HAVING A HUMANIZED TMPRSS GENE | VIVLEMORE, TRACY ANN | 1638 | §112DP | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18543857 | HUMAN LAMBDA LIGHT CHAIN MICE | WILSON, MICHAEL C | 1638 | §112DP | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18535105 | Treatment Of Prion Diseases | ZARA, JANE J | 4100 | §103§112 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18535052 | Treatment Of Type 2 Diabetes With Hepatocyte Nuclear Factor 4 Alpha (HNF4A) Agonists | PERSONS, JENNA L | 4100 | §112 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18528268 | METHODS TO CHARACTERIZING A FRAGMENT CRYSTALLIZABLE DOMAIN OF A BISPECIFIC ANTIBODY | RAMADAN, OMAR | 1678 | §102§103§112 | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18514880 | CELL CULTURE MEDIUM FOR EUKARYOTIC CELLS | KIM, TAEYOON | 1631 | §103§112DP | Final Rejection | 35d | Pending | Nov 20, 2023 |
| 18510900 | Treatment Of Inflammation With Glucocorticoids And Angiopoietin-Like 7 (ANGPTL7) Inhibitors | HUDSON, AMY ROSE | 1636 | §103§112DP | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18509030 | COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES | HUYNH, PHUONG N | 1641 | §112DP | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18389375 | METHODS FOR DETECTING AND EVALUATING VIRUSES AND VIRUS-LIKE PARTICLES | WHITE, DENNIS MICHAEL | 2877 | §102§103 | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18509136 | ANTI-FGFR3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AND METHODS OF USE THEREOF | BENAVIDES, JENNIFER ANN | 1675 | §112Other | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18501865 | CALCIUM VOLTAGE-GATED CHANNEL AUXILIARY SUBUNIT GAMMA 1 (CACNG1) BINDING PROTEINS AND CACNG1-MEDIATED DELIVERY TO SKELETAL MUSCLE | HALVORSON, MARK | 1646 | §112 | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18497352 | METHODS OF TREATING CANCER WITH A COMBINATION OF ADOPTIVE CELL THERAPY AND A TARGETED IMMUNOCYTOKINE | STONEBRAKER, ALYSSA RAE | 1642 | §103§112DP | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18488316 | HSD17B13 VARIANTS AND USES THEREOF | ZAHORIK, AMANDA MARY | 1636 | §112 | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18472847 | GENETICALLY MODIFIED MICE EXPRESSING COMPONENTS OF HUMAN CELLULAR IMMUNE SYSTEM | MOORE, JOHN DAVID | 1638 | §103 | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18367444 | AN AQUEOUS PHARMACEUTICAL FORMULATION INCLUDING A VEGF RECEPTOR FUSION PROTEIN | LOCKARD, JON MCCLELLAND | 1647 | §112 | Non-Final OA | — | Pending | Sep 12, 2023 |
| 18244577 | Treatment Of Endometriosis With R-Spondin 3 (RSPO3) Inhibitors | TATGE, LEXUS MARC | 1637 | §101§112 | Final Rejection | 22d | Pending | Sep 11, 2023 |
| 18549621 | WORKFLOW TO ASSIGN PUTATIVE SOURCE TO DE NOVO PEPTIDE SEQUENCE | SCHULTZHAUS, JANNA NICOLE | — | §101§103§112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18462320 | METHOD OF TREATING AN ALLERGY WITH ALLERGEN-SPECIFIC MONOCLONAL ANTIBODIES | TAYLOR, LIA ELAN | 1641 | §103Other | Non-Final OA | 8d | Pending | Sep 06, 2023 |
| 18459091 | CRISPR/CAS DROPOUT SCREENING PLATFORM TO REVEAL GENETIC VULNERABILITIES ASSOCIATED WITH TAU AGGREGATION | CHONG, KIMBERLY | 1636 | §112 | Non-Final OA | — | Pending | Aug 31, 2023 |
| 18459221 | METHODS OF TREATING NON-SMALL CELL LUNG CANCER USING MESENCHYMAL EPITHELIAL TRANSITION FACTOR (MET)-TARGETED AGENTS | HINES, JANA A | 1645 | §103 | Final Rejection | — | Pending | Aug 31, 2023 |
| 18547192 | METHODS OF TREATING LUNG CANCER BY ADMINISTERING A PD-1 INHIBITOR | HOPKINS, SAMANTHA LAKE | 1641 | §102Other | Final Rejection | 61d | Pending | Aug 21, 2023 |
| 18547150 | METHOD FOR DIAGNOSING AND TREATING PARTIAL LIPODYSTROPHY | TOTH, KAREN E | 3791 | §101§102§103§112 | Non-Final OA | 83d | Pending | Aug 18, 2023 |
| 18234101 | Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-VEGF | KRIANGCHAIVECH, KETTIP | 1672 | §101§112 | Non-Final OA | — | Pending | Aug 15, 2023 |
| 18232238 | HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF | ROONEY, NORA MAUREEN | 1641 | Other | Non-Final OA | — | Pending | Aug 09, 2023 |
| 18264799 | METHODS OF TREATING CANCER BY ADMINISTERING A NEOADJUVANT PD-1 INHIBITOR | SULLIVAN, DENNIS JOHN | 1642 | §103§112DP | Non-Final OA | — | Pending | Aug 09, 2023 |
| 18355108 | Macrophage Stimulating 1 Receptor (MST1R) Variants And Uses Thereof | SCHWECHTER, BRANDON ROSS | 1674 | §112 | Final Rejection | 34d | Pending | Jul 19, 2023 |
| 18223434 | VECTORS, GENETICALLY MODIFIED CELLS, AND GENETICALLY MODIFIED NON-HUMAN ANIMALS COMPRISING THE SAME | CONNORS, ALEXANDRA F | 1634 | §103§112DP | Non-Final OA | — | Pending | Jul 18, 2023 |
| 18221934 | ISOELECTRIC FOCUSING-BASED ENRICHMENT OF CHARGE VARIANT SPECIES | FRITCHMAN, REBECCA M | 1758 | §103 | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18344494 | AUTO-INJECTOR AND RELATED METHODS OF USE | STIGELL, THEODORE J | 3783 | §102 | Final Rejection | — | Pending | Jun 29, 2023 |
| 18340917 | NON-HUMAN ANIMALS HAVING A HUMANIZED CLEC9A GENE | CANDELARIA, JULIANA IRENE | 1634 | §112 | Final Rejection | 12d | Pending | Jun 26, 2023 |
| 18336644 | FAST PROTEIN SEQUENCING | CHEU, CHANGHWA J | 1678 | Other | Non-Final OA | 28d | Pending | Jun 16, 2023 |
| 18336148 | SYSTEMS AND METHODS FOR DRUG DELIVERY TO OCULAR TISSUE | MEDWAY, SCOTT J | 3783 | §102§103 | Non-Final OA | 25d overdue | Pending | Jun 16, 2023 |
| 18324380 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112 | Non-Final OA | — | Pending | May 26, 2023 |
| 18317241 | ANTI-LAG3 ANTIBODIES AND USES THEREOF | OUSPENSKI, ILIA I | 1644 | DP | Final Rejection | 52d overdue | Pending | May 15, 2023 |
| 18197579 | BIOANALYSIS OF THERAPEUTIC ANTIBODIES AND RELATED PRODUCTS USING IMMUNOPRECIPITATION AND NATIVE SEC-PCD-MS DETECTION | SPANGLER, JOSEPH RANKIN | 1656 | §103§112Other | Non-Final OA | — | Pending | May 15, 2023 |
| 18313745 | METHODS AND SYSTEMS FOR CHROMATOGRAPHY DATA ANALYSIS | TCHATCHOUANG, CARL F.R. | 2858 | DP | Non-Final OA | — | Pending | May 08, 2023 |
| 18306737 | Transcriptome Analysis For Treating Inflammation | SMITH, EMILIE ALINE | 1686 | §103§112 | Non-Final OA | — | Pending | Apr 25, 2023 |
| 18133288 | COMPOSITIONS AND METHODS FOR UNIVERSAL TUMOR CELL KILLING | STONEBRAKER, ALYSSA RAE | 1642 | §103§112 | Non-Final OA | — | Pending | Apr 11, 2023 |
| 18130980 | COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST | HOWARD, ZACHARY C | 1674 | §102§103§112 | Non-Final OA | 127d overdue | Pending | Apr 05, 2023 |
| 18129923 | G PROTEIN-COUPLED RECEPTOR 75 (GPR75) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | MEYERING, SHABANA SHABBEER | 1635 | §102§103 | Non-Final OA | 62d | Pending | Apr 03, 2023 |
| 18247226 | COMBINATION OF ANTIBODIES FOR TREATING CANCER WITH REDUCED CYTOKINE RELEASE SYNDROME | STONEBRAKER, ALYSSA RAE | 1642 | §102§103§112DP | Final Rejection | — | Pending | Mar 29, 2023 |
| 18187564 | PRECISION DOSE DELIVERY DEVICE PLUNGER ROD INSERTION GAUGE AND METHODS THEREFOR | NGUYEN, ANDREW H | 3741 | §103§112 | Non-Final OA | 2d overdue | Pending | Mar 21, 2023 |
| 18182323 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | 27d | Pending | Mar 11, 2023 |
| 17969033 | METHODS FOR TREATING PRURIGO NODULARIS BY ADMINISTERING AN IL-4R ANTAGONIST | NATARAJAN, MEERA | 1643 | §103 | Non-Final OA | 4d overdue | Pending | Mar 02, 2023 |
| 18175852 | MANUFACTURING PROCESS FOR HIGH TITER ANTIBODY | GRIZER, CASSANDRA SENN | 1672 | §103§112DP | Non-Final OA | — | Pending | Feb 28, 2023 |
| 18115354 | CELL CULTURE METHODS FOR ANTIBODY PRODUCTION | MCKNIGHT, CIARA A | 1656 | §103§112DP | Final Rejection | — | Pending | Feb 28, 2023 |
| 18115285 | BIOREACTOR FOR ANTIBODY PRODUCTION | CANDELARIA, JULIANA IRENE | 1634 | §103§112 | Final Rejection | 21d | Pending | Feb 28, 2023 |
| 18114057 | Dosing Regimens for Mitigation of Cytokine Release Syndrome | SHUPE, ELIZABETH A | 1643 | §103§112DP | Non-Final OA | — | Pending | Feb 24, 2023 |
| 18042441 | METHODS OF TREATING CANCER BY ADMINISTERING A PD-1 INHIBITOR | AEDER, SEAN E | 1642 | §103 | Non-Final OA | 42d | Pending | Feb 21, 2023 |
| 18105772 | Stabilized Formulations Containing Anti-IL-33 Antibodies | KIM, YUNSOO | 1641 | §103 | Non-Final OA | — | Pending | Feb 03, 2023 |
| 18163698 | ANTI-TFR:GAA AND ANTI-CD63:GAA INSERTION FOR TREATMENT OF POMPE DISEASE | JOHNSON, TIRONE DEREK | 1675 | §103§112 | Non-Final OA | — | Pending | Feb 02, 2023 |
| 18159445 | DRUG DELIVERY DEVICE SAFETY SYSTEM | TRINH, HONG-VAN N | 3783 | §103 | Non-Final OA | — | Pending | Jan 25, 2023 |
| 18157587 | Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors | CASH, KAILEY ELIZABETH | 1683 | §102§103DP | Non-Final OA | 32d overdue | Pending | Jan 20, 2023 |
| 18095839 | Methods for Improving Resolution of Heterodimeric Proteins from Impurities Using Affinity Chromatography | IANNUZO, NATALIE NMN | 1653 | §103 | Final Rejection | — | Pending | Jan 11, 2023 |
| 18152346 | Triggering Receptor Expressed On Myeloid Cells 2 (TREM2) Variants And Uses Thereof | SALMON, KATHERINE D | 1682 | §102§103§112 | Non-Final OA | — | Pending | Jan 10, 2023 |
| 18095467 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | CANELLA, KAREN A | 1643 | §103§112 | Final Rejection | 20d | Pending | Jan 10, 2023 |
| 18069110 | OFF-TARGET PREDICTION METHOD FOR ANTIGEN-RECOGNITION MOLECULES BINDING TO MHC-PEPTIDE TARGETS | LEVERETT, MARY CHANG | 1687 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 20, 2022 |
| 18059719 | Treatment Of Lung Disease Based Upon Stratification Of Polygenic Score Relating To Response To A Therapeutic Agent | GODDARD, LAURA B | 1642 | §101§103§112 | Non-Final OA | — | Pending | Nov 29, 2022 |
| 18057298 | Methods Of Treating Headaches And Migraines With Sodium Voltage-Gated Channel Alpha Subunit 11 (SCN11A) Inhibitors | TATGE, LEXUS MARC | 1637 | §101§112 | Final Rejection | — | Pending | Nov 21, 2022 |
| 18055895 | AUTO-INJECTOR AND RELATED METHODS OF USE | GONZALEZ, LEI NMN | 3783 | §103 | Non-Final OA | 39d | Pending | Nov 16, 2022 |
| 18051488 | Association Of T Cell Leukemia/Lymphoma Protein 1A (TCL1A) With Clonal Hematopoiesis Of Indeterminate Potential (CHIP) | KAPUSHOC, STEPHEN THOMAS | 1683 | §103§112 | Non-Final OA | 73d overdue | Pending | Oct 31, 2022 |
| 17920069 | NON-HUMAN ANIMALS HAVING A HUMANIZED CXCL13 GENE | DHAR, MATASHA | 1632 | §103 | Non-Final OA | 46d overdue | Pending | Oct 20, 2022 |
| 17936715 | Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) Inhibitors | ANGELL, JON E | 1637 | §112 | Final Rejection | 13d | Pending | Sep 29, 2022 |
| 17954999 | ASSAYS TO QUANTITATE DRUG AND TARGET CONCENTRATIONS | EVANS, CHRISTOPHER RYAN | 1677 | §102§103§112 | Final Rejection | 4d overdue | Pending | Sep 28, 2022 |
| 17934277 | Methods Of Treating Chronic Kidney Disease (CKD) With Inhibitors Of Protective Loss-Of-Function Genes | KENYON, JOHN S | 1625 | §112 | Non-Final OA | 49d overdue | Pending | Sep 22, 2022 |
| 17948382 | METHODS OF CONTROLLING ANTIBODY HETEROGENEITY | O'NEILL, MARISOL ANN | 1633 | §102§103 | Non-Final OA | — | Pending | Sep 20, 2022 |
| 17933148 | ANTI-C5 ANTIBODIES AND USES THEREOF | ALAWADI, SARAH | 1619 | §112 | Non-Final OA | — | Pending | Sep 19, 2022 |
| 17930471 | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS | XU, XIAOYUN | 1797 | §103 | Final Rejection | — | Pending | Sep 08, 2022 |
| 17821806 | Treatment Of Inflammatory Diseases With RAS Protein Activator Like 3 (RASAL3) Inhibitors | VYAS, KEYUR ANILKUMAR | 1637 | §112 | Non-Final OA | — | Pending | Aug 24, 2022 |
| 17887565 | IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | DONOGHUE, BRITTNEY ERIN | 1675 | §103 | Non-Final OA | 15d overdue | Pending | Aug 15, 2022 |
| 17885805 | MASS SPECTROMETRY-BASED STRATEGY FOR DETERMINING PRODUCT-RELATED VARIANTS OF A BIOLOGIC | WHITE, ASHLEY TAYLOR | 1653 | §101§103§112 | Final Rejection | 13d | Pending | Aug 11, 2022 |
| 17759539 | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS COMPRISING A V30M MUTATION AND METHODS OF USE | PENNINGTON, KATIE LEIGH | 1634 | §103§112 | Final Rejection | — | Pending | Jul 27, 2022 |
| 17870368 | NATIVE MICROFLUIDIC CE-MS ANALYSIS OF ANTIBODY CHARGE HETEROGENEITY | XU, XIAOYUN | 1797 | §103Other | Final Rejection | 55d | Pending | Jul 21, 2022 |
| 17813100 | COMBINATION OF CHECKPOINT INHIBITORS AND AN ONCOLYTIC VIRUS FOR TREATING CANCER | MOSELEY II, NELSON B | 1642 | §103 | Final Rejection | — | Pending | Jul 18, 2022 |
| 17863303 | MASS SPECTROMETRY-BASED STRATEGY FOR DETERMINING PRODUCT-RELATED VARIANTS OF A BIOLOGIC | WHITE, ASHLEY TAYLOR | 1653 | §101§103DP | Non-Final OA | — | Pending | Jul 12, 2022 |
| 17862240 | Methods for Viral Particle Characterization Using Two-Dimensional Liquid Chromatography-Mass Spectrometry | ZOU, NIANXIANG | 1671 | §103§112 | Final Rejection | 20d | Pending | Jul 11, 2022 |
| 17782508 | VEGF MINI-TRAPS AND METHOD OF USE THEREOF | DABKOWSKI, ERINNE R | 1654 | §103§112DP | Non-Final OA | — | Pending | Jun 03, 2022 |
| 17735510 | MULTISPECIFIC FGF21 RECEPTOR AGONISTS AND THEIR USES | SAOUD, CHRISTINE J | 1600 | §112 | Non-Final OA | — | Pending | May 03, 2022 |
| 17734688 | BIOCHEMICAL ASSAYS FOR THERAPEUTIC PROTEINS | HALVORSON, MARK | 1646 | §102 | Final Rejection | — | Pending | May 02, 2022 |
| 17716154 | MEASUREMENT OF THERAPEUTIC PROTEINS CO-ADMINISTERED TO A SUBJECT BY LC-MRM-MS ASSAY | CONSTANTINE, CHARLES Z | 1657 | §103§112 | Non-Final OA | — | Pending | Apr 08, 2022 |
| 17684674 | SYSTEMS AND METHODS FOR QUANTIFYING AND MODIFYING PROTEIN VISCOSITY | XU, XIAOYUN | 1797 | §103 | Non-Final OA | 31d overdue | Pending | Mar 02, 2022 |
| 17591355 | Systems and Methods for Sequencing T Cell Receptors and Uses Thereof | ZEMAN, MARY K | 1686 | §101§103§112DP | Non-Final OA | — | Pending | Feb 02, 2022 |
| 17584642 | Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors | SUNSHINE, HANNAH LOUISE | 1647 | §112Other | Final Rejection | — | Pending | Jan 26, 2022 |
| 17579185 | RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN MICE | WEHBE, ANNE MARIE SABRINA | 1634 | Other | Non-Final OA | — | Pending | Jan 19, 2022 |
| 17615732 | MODIFIED DOSAGE OF SUBCUTANEOUS TOCILIZUMAB FOR RHEUMATOID ARTHRITIS | DENT, ALANA HARRIS | 1643 | §103 | Non-Final OA | — | Pending | Dec 01, 2021 |
| 17612669 | MODIFIED VIRAL PARTICLES AND USES THEREOF | RIGA, MICHAEL ANGELO | 1634 | §102§103§112 | Non-Final OA | — | Pending | Nov 19, 2021 |
| 17612204 | TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF | STONEBRAKER, ALYSSA RAE | 1642 | §103§112 | Non-Final OA | — | Pending | Nov 17, 2021 |
| 17492490 | CONTINUOUS VIRUS RETENTIVE FILTRATION | PEO, KARA M | 1777 | §103§112 | Non-Final OA | — | Pending | Oct 01, 2021 |
| 17476078 | Use of LEPR Agonists for Pain | CHERNYSHEV, OLGA N | 1675 | §112 | Final Rejection | — | Pending | Sep 15, 2021 |
| 17433887 | ADENO-ASSOCIATED VIRUS VECTORS FOR THE DELIVERY OF THERAPEUTICS | LEONARD, ARTHUR S | 1631 | §103§112 | Non-Final OA | 6d | Pending | Aug 25, 2021 |
| 17356497 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | CANELLA, KAREN A | 1643 | §102§103§112 | Final Rejection | 8d | Pending | Jun 23, 2021 |
| 17244864 | METHODS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | HOPKINS, SAMANTHA LAKE | 1641 | §103§112Other | Final Rejection | — | Pending | Apr 29, 2021 |
| 17236998 | METHODS AND SYSTEMS FOR ANALYSIS OF RECEPTOR INTERACTION | SABOUR, GHAZAL | 1686 | §103 | Final Rejection | 4d overdue | Pending | Apr 21, 2021 |
| 17183904 | COMPOSITIONS COMPRISING IL6R ANTIBODIES FOR THE TREATMENT OF UVEITIS AND MACULAR EDEMA AND METHODS OF USING SAME | FAUST, AMBER KATHLEEN | 1643 | §103 | Non-Final OA | 33d | Pending | Feb 24, 2021 |
| 17268719 | METHOD AND CHROMATOGRAPHY SYSTEM FOR DETERMINING AMOUNT AND PURITY OF A MULTIMERIC PROTEIN | GERMAIN, ADAM ADRIEN | 1777 | §103 | Final Rejection | — | Pending | Feb 16, 2021 |
| 17113485 | GENETICALLY MODIFIED MICE THAT EXPRESS HUMANIZED IgG1 LACKING A CH1 DOMAIN AND HUMANIZED UNIVERSAL LIGHT CHAIN | WILSON, MICHAEL C | 1638 | §112 | Final Rejection | — | Pending | Dec 07, 2020 |
| 17112198 | METHODS FOR TREATING COPD BY ADMINISTERING AN IL-33 ANTAGONIST | BENAVIDES, JENNIFER ANN | 1675 | §103 | Non-Final OA | — | Pending | Dec 04, 2020 |
| 17062375 | High-throughput method to screen cognate T cell and epitope reactivities in primary human cells | YOUNG, BRIAN ELLIS | 1684 | §103 | Final Rejection | 30d | Pending | Oct 02, 2020 |
| 17041252 | GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS OF MAKING AND USES THEREOF | WILSON, MICHAEL C | 1638 | §103§112 | Non-Final OA | 4d overdue | Pending | Sep 24, 2020 |
| 16993434 | HIGH CONCENTRATION ANTI-C5 FORMULATIONS | ESSEX, LAURA ANN | 1675 | §103§112 | Non-Final OA | 53d | Pending | Aug 14, 2020 |
| 16984531 | METABOLICALLY OPTIMIZED CELL CULTURE | SCHUBERG, LAURA J | 1631 | §103Other | Non-Final OA | — | Pending | Aug 04, 2020 |
| 16882453 | CHARACTERIZATION OF DOMAIN-SPECIFIC CHARGE VARIANTS OF ANTIBODIES | NGUYEN, HENRY H | 1758 | §101§103§112 | Non-Final OA | — | Pending | May 23, 2020 |
| 16880736 | METHODS FOR IDENTIFYING AND QUANTITATING HOST CELL PROTEIN | MARCSISIN, ELLEN JEAN | 1677 | §103 | Non-Final OA | — | AI Ready | May 21, 2020 |
| 16863800 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-33 ANTAGONIST | JOHANSEN, PETER N. | 1644 | §103DP | Final Rejection | — | Pending | Apr 30, 2020 |
| 16644650 | Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) Variants And Uses Thereof | SITTON, JEHANNE SOUAYA | 1682 | §103§112 | Non-Final OA | — | Pending | Mar 05, 2020 |
| 16625207 | Tropism-Modified Recombinant Viral Particles and Uses Thereof for the Targeted Introduction of Genetic Material into Human Cells | GROOMS, TIFFANY NICOLE | 1637 | §103§112 | Non-Final OA | — | Pending | Dec 20, 2019 |
| 16278611 | GAN-CNN FOR MHC PEPTIDE BINDING PREDICTION | BICKHAM, DAWN MARIE | 1685 | §101§103§112 | Final Rejection | — | Pending | Feb 18, 2019 |
| 15766586 | STABLE PROTEIN COMPOSITIONS | SAEED, ALI S | 1616 | §103§112 | Non-Final OA | 83d | Pending | Apr 06, 2018 |
| 15034531 | COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME | PAK, MICHAEL D | 1674 | §103§112DP | Non-Final OA | — | Pending | May 04, 2016 |
| 15130780 | METABOLICALLY OPTIMIZED CELL CULTURE | SCHUBERG, LAURA J | 1631 | §103Other | Non-Final OA | — | Pending | Apr 15, 2016 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial